Latest Insider Transactions at Akero Therapeutics, Inc. (AKRO)
This section provides a real-time view of insider transactions for Akero Therapeutics, Inc. (AKRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Akero Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Akero Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 16
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.99%
|
$530,000
$53.17 P/Share
|
|
Jul 16
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.97%
|
$190,000
$19.87 P/Share
|
|
Jul 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.76%
|
$1,530,000
$51.15 P/Share
|
|
Jul 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.34%
|
$637,500
$51.85 P/Share
|
|
Jul 07
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.51%
|
$262,500
$21.09 P/Share
|
|
Jul 01
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
2,000
-6.27%
|
$104,000
$52.88 P/Share
|
|
Jun 30
2025
|
Andrew Cheng President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.16%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
Scott A. Gangloff Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
299
+1.24%
|
$6,877
$23.87 P/Share
|
|
Jun 30
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.53%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
William Richard White Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+1.5%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
193
+0.6%
|
$4,439
$23.87 P/Share
|
|
Jun 30
2025
|
Jonathan Young Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.45%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
Catriona Yale Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.96%
|
$20,470
$23.87 P/Share
|
|
Jun 20
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
875
-2.69%
|
$47,250
$54.59 P/Share
|
|
Jun 18
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,453
-0.73%
|
$78,462
$54.84 P/Share
|
|
Jun 18
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,633
-1.77%
|
$88,182
$54.84 P/Share
|
|
Jun 18
2025
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,634
-2.76%
|
$88,236
$54.84 P/Share
|
|
Jun 18
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,129
-0.67%
|
$60,966
$54.84 P/Share
|
|
Jun 18
2025
|
Scott A. Gangloff Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
848
-3.49%
|
$45,792
$54.84 P/Share
|
|
Jun 18
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
6,620
-1.19%
|
$357,480
$54.84 P/Share
|
|
Jun 16
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
2,000
-2.93%
|
$108,000
$54.46 P/Share
|
|
Jun 16
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+5.47%
|
$38,000
$19.87 P/Share
|
|
Jun 16
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-3.35%
|
$540,000
$54.7 P/Share
|
|
Jun 16
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.91%
|
$210,000
$21.1 P/Share
|
|
Jun 10
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,493
-1.24%
|
$132,129
$53.99 P/Share
|
|
Jun 10
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
919
-2.74%
|
$49,626
$54.0 P/Share
|
|
Jun 10
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,803
-2.95%
|
$151,362
$54.0 P/Share
|
|
Jun 10
2025
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,804
-4.53%
|
$148,612
$53.99 P/Share
|
|
Jun 10
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,358
-1.39%
|
$127,332
$54.0 P/Share
|
|
Jun 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
37,837
-2.17%
|
$2,043,198
$54.03 P/Share
|
|
Jun 06
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-12.84%
|
$1,375,000
$55.04 P/Share
|
|
Jun 06
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.72%
|
$525,000
$21.1 P/Share
|
|
Jun 05
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.48%
|
$662,500
$53.61 P/Share
|
|
Jun 05
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.42%
|
$262,500
$21.1 P/Share
|
|
Jun 03
2025
|
G. Walmsley Graham |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+44.83%
|
-
|
|
Jun 03
2025
|
Chou Judy |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 03
2025
|
Tomas J. Heyman |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 03
2025
|
Yuan Xu |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 03
2025
|
Mark T Iwicki |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 03
2025
|
Seth Loring Harrison |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+6.06%
|
-
|
|
Jun 03
2025
|
Jane Henderson |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 02
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
4,000
-3.61%
|
$200,000
$50.3 P/Share
|
|
Jun 02
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+9.64%
|
$76,000
$19.87 P/Share
|
|
May 22
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
4,000
-10.67%
|
$200,000
$50.0 P/Share
|
|
May 22
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+9.64%
|
$176,000
$44.37 P/Share
|
|
May 15
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-3.28%
|
$390,000
$39.19 P/Share
|
|
May 15
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.69%
|
$210,000
$21.1 P/Share
|
|
May 12
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.42%
|
$1,230,000
$41.32 P/Share
|
|
May 07
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
8,000
-10.15%
|
$336,000
$42.54 P/Share
|
|
May 07
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+16.16%
|
$152,000
$19.87 P/Share
|